Spondyloarthropathies News

COVID-19 outcomes are worse among patients with inflammatory arthritis receiving glucocorticoids, but not in those receiving anticytokine therapy, according to data published in Arthritis & Rheumatology.

IL-17 inhibitors have recently demonstrated “quite effective” results in treating ankylosing spondylitis, according to a speaker at the 2020 Congress of Clinical Rheumatology-East.

Patients with immune checkpoint therapy-induced inflammatory arthritis report significant social, functional and emotional impacts, compared with cancer and other side effects, according to findings published in BMC Rheumatology.

The risk for hospital-diagnosed COVID-19 among patients with autoimmune or immune-mediated disease may depend on age, specific disease and prior therapy, according to data published in the Annals of the Rheumatic Diseases.

The European Commission has extended approval for Celltrion Healthcare’s subcutaneous infliximab biosimilar to treat adults with ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and psoriasis.

Patients with complex, but not well-known diseases often find themselves at a loss for two important things: A voice and access to reliable information about their condition. Interestingly, the physicians who treat these patients often feel the same way.

Baseline smoking is strongly associated with worse MRI sacroiliac joint inflammation among blue-collar or “low education” patients with axial spondyloarthritis, according to data published in Arthritis & Rheumatology.

Synovitis, acne, pustulosis, hyperostosis, osteomyelitis — collectively known as SAPHO syndrome — in pustular psoriasis remains for most rheumatologists a rare enigma with an unclear pathogenesis, according to Philip Helliwell, PhD, DM, BM BCh, FRCP, MA, of the University of Leeds.

The incidence and severity of COVID-19 among patients with rheumatic disease treated with targeted synthetic or biological DMARDs is consistent with those in the general population, according to data published in Arthritis & Rheumatology.

The FDA has approved the sixth biosimilar to adalimumab, adalimumab-fkjp, for all eligible indications of the biologic product, according to a company press release.